eNOS (NOS3) (NM_000603) Human Tagged ORF Clone Lentiviral Particle

SKU RC209228L4V

Lenti ORF particles, NOS3 (mGFP-tagged) - Human nitric oxide synthase 3 (endothelial cell) (NOS3), transcript variant 1, 200ul, >10^7 TU/mL

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: mGFP
• Target Symbol: eNOS
• Synonyms: ECNOS; eNOS
• Vector: pLenti-C-mGFP-P2A-Puro
• Mammalian Cell Selection: Puromycin
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC209228).
• ACCN: NM_000603
• ORF Size: 3609 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
• Shipping: Dry Ice

Reference Data

• RefSeq: NM_000603.3
• RefSeq Size: 4345 bp
• RefSeq ORF: 3612 bp
• Locus ID: 4846
• UniProt ID: P29474
• Cytogenetics: 7q36.1
• Domains: FAD_binding_1, flavodoxin, NAD_binding_1, NO_synthase
• Protein Families: Druggable Genome
• Protein Pathways: Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Arginine and proline metabolism, Calcium signaling pathway, Long-term depression, Metabolic pathways, Pathways in cancer, Small cell lung cancer, VEGF signaling pathway
• MW: 133.3 kDa
• Summary: Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Oct 2016]